Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study.

Abstract

Buspirone, a new anxiolytic agent, was used in a multiple-baseline, placebo lead-in study for the treatment of aggression and anxiety in six mentally retarded adult patients. The findings demonstrate buspirone's effectiveness in reducing aggression and anxiety in a mentally retarded group of subjects without causing deleterious cognitive side effects. The authors review a body of literature on animal and human subjects where buspirone was used in the treatment of aggression and other mental disorders. Unlike neuroleptics and benzodiazepines, buspirone does not cause sedation which can compromise adaptive and intellectual capacities and thus reduce the patient's potential to benefit from training programs.

• Authors: J Ratey, R Sovner, A Parks, K Rogentine
• Journal: The Journal of clinical psychiatry (J Clin Psychiatry) Vol. 52 Issue 4 Pg. 159-62 (Apr 1991) ISSN: 0160-6689 [Print] United States
• PMID: 2016248 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Placebos
• Buspirone

Topics

• Adult
• Aggression (drug effects)
• Anxiety Disorders (complications, drug therapy, psychology)
• Buspirone (pharmacology, therapeutic use)
• Dose-Response Relationship, Drug
• Female
• Humans
• Intellectual Disability (complications, psychology)
• Male
• Middle Aged
• Placebos
• Psychological Tests